Pacira Pharma (PCRX) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Pacira Pharma (PCRX) Misses Q4 EPS by 3c

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

February 28, 2023 8:00 AM EST

Record revenues of $667 million in 2022

Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million

EXPAREL surpasses the 12 million patient mark

Conference call today at 8:30 a.m. ET

TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.

2022 was a solid year for Pacira as we posted record revenue and significant... More